Firstly, it was proved that non-selective AURKA and AURKB inhibitors GW809897X and GW806742X treatment reduced cell proliferation of leukemia cell line (K-562) with a potency constant IC50 of > 5 μM and 1.47 μM, respectively. The gene discussed is AURKA; the disease is leukemia.